一体式膜-生物反应器长期运行中的膜污染控制

考察一体式膜－生物反应器运行过程中的膜污染情况,探讨造成膜污染的原因和膜污染的控制方法．结果表明,膜内表面微生物的滋生和膜外表面污泥层的附着是造成本试验膜污染的重要因素．采用２％ ～５％ 的次氯酸钠溶液进行在线药洗可以有效地去除膜内表面滋生的微生物,使膜过滤压差下降７．７～５２ｋＰａ;停止进出水,加大曝气量进行空曝气是去除膜外表面附着污泥层的重要手段,可以使膜过滤压差下降３．８～１０．８ｋＰａ;采用处理出水进行反冲洗虽然有时可以使膜过滤压差出现较大程度的降低,但随之会出现出水水质恶化,膜过滤压差急剧升高的现象．     

浅析水体富营养化的生态修复技术

通过对目前国内外针对湖泊富营养化的恢复技术的分析,提出水体富营养化生态修复技术存在的问题,提出了水体富营养化生态修复的设想.     

萃取膜生物反应器处理苯酚废水的试验研究

从经过驯化的活性污泥中筛选出苯酚降解菌.制备成菌悬液,对比活性污泥体系和菌悬液体系的萃取膜生物反应器(EMB)对苯酚废水的处理效果,考察了料液苯酚浓度、反应器温度等因素对膜萃取速率及生物降解效果的影响.结果表明,通过以苯酚为唯一碳源,逐渐提高苯酚浓度的方法对活性污泥进行驯化.当进水苯酚浓度为700 mg·L-1时,苯酚去除率达99%以上;适当提高反应器温度和料液初始浓度有利于提高膜萃取速率;当初始料液苯酚浓度为2000 mg·L-1时,膜萃取速率高于生物降解速率,生物相中产生苯酚积累;菌悬液体系EMB的生物膜厚度明显小于活性污泥体系,且水力反冲洗可有效控制生物膜厚度.对苯酚生物降解产物的GC-MS分析结果表明,苯酚的生物降解较彻底,基本无苯酚中间产物的残留.     

新型单室无质子膜微生物燃料电池性能研究

采用不锈钢金属丝阳极构建了管状单室无质子交换膜空气阴极微生物燃料电池(MFC),并以葡萄糖为唯一电子供体,研究MFC的性能.在室温下,初始ρ(CODCr)为496 mg/L,外接电阻为1 000 Ω时,该MFC可以连续产电,最高电压达235.11 mV,开路电压为461.00 mV,内电阻约2 820 Ω.实验条件下测得该MFC的最大功率密度为137.1 mW/m2,库仑效率为32.4%.采用该MFC进行了啤酒酿造废水处理对比实验,在进水ρ(CODCr)为15 900 mg/L,停留时间为96 h下,MFC对废水CODCr的去除率达40%～55%,比厌氧生物处理效率高5%～10%.表明MFC技术可以在获得电能的同时,强化有机废水的生物处理过程.     

曝气强度对膜生物反应器污泥混合液可滤性的影响

主要研究了曝气强度对膜生物反应器(MBR)膜污染的影响.2套MBR采用恒流出水模式连续运行60 d,曝气强度分别为500及100 L/h,应用死端过滤装置来检测不同阶段污泥混合液的可滤性.实验中对不同曝气强度下的溶解性微生物代谢产物(SMP)分子质量分布、颗粒粒径分布、胞外聚合物(EPS)含量进行了测定.结果表明,过高的曝气强度将恶化污泥混合液的可滤性,增加了膜污染速率.进一步研究表明,曝气强度的增加导致了污泥混合液上清液中相对分子质量>10000的SMP浓度的增加,此部分大分子有机物浓度直接影响了污泥混合液的可滤性.过高的曝气强度也导致了污泥絮体中1～10μm细小颗粒和EPS含量的增加.     

生物除锰技术研究进展与应用

文章简要阐述了生物除锰的机理,重点介绍生物除锰的工艺流程和应用,包括以生物滤池为核心的单极/多级工艺、复合MF/UF中空纤维膜工艺以及用于处理矿山废水的人工湿地工艺;同时介绍了国内外生物除锰的研究动态,如:同时去除NH4+、Fe、Mn的研究、生物滤池运行模式的研究等。分析了目前存在的问题,并对今后生物除锰的研究方向提出了一点看法。     

内置转盘式PVDF膜生物反应器污水处理的试验研究

对内置转盘式PVDF膜生物反应器(SRMBR)处理污水工艺及膜清洗进行了研究.SRMBR处理污水可以长期稳定运行,在实验模拟污水COD为180～368 mg/L时,出水COD在运行1d后稳定在20 mg/L以内,COD去除率>93%.增大转盘式平板膜组件转速可以增大SRMBR的平衡水通量,转速从15 r/min增大到25 r/min,平衡水通量从42.5 L/(m2·h)增大到47.5L/(m2·h).在一定自吸泵停抽时间内(0～1 min),延长停抽时间有利于减缓膜污染、提高平衡水通量.对污染的膜进行水洗、水洗 碱洗、水洗 碱洗 酸洗,3种清洗方式分别使膜平衡水通量恢复至新膜平衡水通量的48.4%、83.5%、90.2%.     

Prenatal diagnosis of cystic fibrosis: I. Prospective study of 51 pregnancies

A prenatal diagnosis was performed in 51 pregnancies with a 1-in-4 risk of having a child with cystic fibrosis. The criteria for determining an affected fetus were based on the results of alkaline phosphatase (ALP) residual activity after inhibition by phenylalanine and by homoarginine, of total ALP activity, and of gamma-glutamyltranspeptidase (GGTP) activity in the amniotic fluid taken between 16 and 19 weeks of pregnancy. The chromosomal analysis of amniotic fluid cells showed trisomy 13 in one case which was excluded from the analysis of biochemical assays. The biochemical assays were in the normal ranges in the amniotic fluid of 35 pregnancies: 26 have reached term and a normal infant has been born, 9 are still in progress. A deficiency of the ALP phenylalanine-inhibitable form, depressed values of total ALP and GGTP were observed in the amniotic fluid of 15 pregnancies: one pregnancy went to term and the infant had CF, in 14 cases the pregnancy was terminated, and meconium ileus was observed in ten of these cases. It was observed that the changes towards abnormal values became more significant with advancing gestational age and that 18 weeks appeared to be the optimum time for diagnostic amniocentesis.     

Successful outcome of pregnancy after treatment of maternal anti-ro (SSA) antibodies with immunosuppressive therapy and plasmapheresis

In this short communication we describe a patient with anti-SSA and anti-SSB antibodies whose first child died of congenital complete heart block (CCHB). During her second pregnancy she was treated with prednisolone, azathioprine, and plasmapheresis, and levels of anti-SSA and anti-SSB antibodies fell significantly. The pregnancy evolved uneventfully and resulted in the birth of an unaffected male infant. This is the fourth reported case of a successful outcome of pregnancy after treatment with immunosuppressive drugs in a woman with a significant risk of recurrence of CCHB.     

An evaluation of a shared experience group for women and their support persons following prenatal diagnosis and termination for a fetal abnormality

Objectives Support after fetal diagnosis of abnormality (SAFDA), is a facilitated shared experience group for women and their partners or support person, in Victoria, Australia, who have had a pregnancy termination for a fetal abnormality. The objective of this study was to evaluate the SAFDA-facilitated group. Methods A questionnaire-based study was undertaken between 2001 and 2005 to evaluate SAFDA. A deidentified self-completed questionnaire was given to participants at the end of each group and included questions relating to the referring professional, participants' prior expectations of the group, helpfulness of participation, preferred group format, length, and venue. In addition, there was also opportunity for participants to make general comments on their experiences of participating in SAFDA. Results A total of 85 participants (100% response) completed the questionnaire. Seventy-one participants (84%) considered it ‘very helpful’ to participate in the group. Seventy-eight participants (92%) considered that a shared-experience group was the most beneficial format. Comments written by participants affirmed that the present format of SAFDA was a highly valued opportunity to listen to and share experiences in a confidential small group. Conclusion SAFDA is a beneficial forum for women and their partners or support person to share their experiences after having had a pregnancy termination for a fetal abnormality. Further, SAFDA provides information and insights for health professionals who are considering how best to support women. Copyright © 2007 John Wiley & Sons, Ltd.